کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2523674 1557961 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN
چکیده انگلیسی

PurposeMicroRNA-454 has been proven dysregulated in some human malignancies and correlated with tumor progression. However, its expression and function in non-small cell lung cancer (NSCLC) is still unclear. Thus, the aim of this study was to explore the effects of miR-454 in NSCLC tumorigenesis and development.MethodsUsing quantitative RT-PCR, we detected miR-454 expression in NSCLC cell lines and primary tumor tissues. The association of miR-454 expression with clinicopathological factors and prognosis was also analyzed. Then, the effects of miR-454 on the biological behavior of NSCLC cells were investigated. At last, the potential regulatory function of miR-454 on PTEN expression was confirmed.ResultsmiR-454 was found to be up-regulated in NSCLC tissues and cell lines. High miR-454 expression was closely correlated with lymph node metastasis, advanced TNM stage, and shorter overall survival. Multivariate regression analysis corroborated that miR-454 overexpression was an independent unfavourable prognostic factor for patients with NSCLC. Down-regulation of miR-454 could significantly reduce NSCLC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while up-regulation of miR-454 showed opposite effects. Further, PTEN was confirmed as a direct target of miR-454 by using Luciferase Reporter Assay.ConclusionsThese findings indicate that miR-454 may act as an oncogene in NSCLC and would serve as a potential therapy target for this disease.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biomedicine & Pharmacotherapy - Volume 81, July 2016, Pages 79–85
نویسندگان
, , , , , , , , ,